<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(10)</volume><submitter>Lan M</submitter><pubmed_abstract>Myocardial ischemia reperfusion (IR) injury is closely related to the overwhelming inflammation in the myocardium. Herein, cardiomyocyte-targeted nanotherapeutics were developed for the reactive oxygen species (ROS)-ultrasensitive co-delivery of dexamethasone (Dex) and RAGE small interfering RNA (siRAGE) to attenuate myocardial inflammation. PPTP, a ROS-degradable polycation based on PGE&lt;sub>2&lt;/sub>-modified, PEGylated, ditellurium-crosslinked polyethylenimine (PEI) was developed to surface-decorate the Dex-encapsulated mesoporous silica nanoparticles (MSNs), which simultaneously condensed siRAGE and gated the MSNs to prevent the Dex pre-leakage. Upon intravenous injection to IR-injured rats, the nanotherapeutics could be efficiently transported into the inflamed cardiomyocytes via PGE&lt;sub</pubmed_abstract><journal>Nano research</journal><pagination>9125-9134</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9328183</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cardiomyocyte-targeted anti-inflammatory nanotherapeutics against myocardial ischemia reperfusion (IR) injury.</pubmed_title><pmcid>PMC9328183</pmcid><pubmed_authors>Hou M</pubmed_authors><pubmed_authors>Yan J</pubmed_authors><pubmed_authors>Dang J</pubmed_authors><pubmed_authors>Deng Q</pubmed_authors><pubmed_authors>Lv S</pubmed_authors><pubmed_authors>Lan M</pubmed_authors><pubmed_authors>Ji Y</pubmed_authors><pubmed_authors>Yin M</pubmed_authors><pubmed_authors>Zhao Z</pubmed_authors><pubmed_authors>Yin L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cardiomyocyte-targeted anti-inflammatory nanotherapeutics against myocardial ischemia reperfusion (IR) injury.</name><description>Myocardial ischemia reperfusion (IR) injury is closely related to the overwhelming inflammation in the myocardium. Herein, cardiomyocyte-targeted nanotherapeutics were developed for the reactive oxygen species (ROS)-ultrasensitive co-delivery of dexamethasone (Dex) and RAGE small interfering RNA (siRAGE) to attenuate myocardial inflammation. PPTP, a ROS-degradable polycation based on PGE&lt;sub>2&lt;/sub>-modified, PEGylated, ditellurium-crosslinked polyethylenimine (PEI) was developed to surface-decorate the Dex-encapsulated mesoporous silica nanoparticles (MSNs), which simultaneously condensed siRAGE and gated the MSNs to prevent the Dex pre-leakage. Upon intravenous injection to IR-injured rats, the nanotherapeutics could be efficiently transported into the inflamed cardiomyocytes via PGE&lt;sub</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-05T08:55:59.204Z</modification><creation>2025-04-05T08:55:59.204Z</creation></dates><accession>S-EPMC9328183</accession><cross_references><pubmed>35915748</pubmed><doi>10.1007/s12274-022-4553-6</doi></cross_references></HashMap>